Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases
摘要:
A series of chlamydocin analogs with various carbonyl functionalities were designed and synthesized as histone deacetylase (HDAC) inhibitors. Chlamyclocin is a cyclic tetrapeptide containing an epoxyketone surrogate in the side chain which makes it irreversible inhibitor of HDACs, whereas apicidins are a class of cyclic tetrapeptides that contain an ethylketone moiety as zinc ligand. We replaced the epoxyketone moiety of chlamydocin with several ketones and aldehyde to synthesize potent reversible and selective HDAC inhibitors. The inhibitory activity of the cyclic tetrapeptides against histone deacetylase enzymes were evaluated and the result showed most of them are potent inhibitors. Some of them have remarkable selectivity among the HDACs. (c) 2006 Published by Elsevier Ltd.
Cyclic tetrapeptides with –SS– bridging between amino acid side chains for potent histone deacetylases’ inhibition
作者:Toru Arai、Md. Ashraful Hoque、Norikazu Nishino、Hyun-Jung Kim、Akihiro Ito、Minoru Yoshida
DOI:10.1007/s00726-013-1527-8
日期:2013.10
Cyclic depsipeptide FK228 with an intramolecular disulfide bond is a potent inhibitor of histone deacetylases (HDAC). FK228 is stable in blood because of its prodrug function, whose –SS– bond is reduced within the cell. Here, cyclic peptides with –SS– bridges between a variety of amino acids were synthesized and assayed for HDAC inhibition. Cyclic peptide 3, cyclo(-l-amino acid-l-amino acid-l-Val-d-Pro-)
具有分子内二硫键的环状二肽FK228是组蛋白脱乙酰基酶(HDAC)的有效抑制剂。由于FK228的前药功能,其在细胞内的–SS–键减少,因此在血液中稳定。在这里,合成了在多种氨基酸之间带有–SS–桥的环状肽,并检测了其对HDAC的抑制作用。环肽3,环( -升-氨基酸升-氨基酸升-Val- d -Pro-),与第一和第二个氨基酸之间的-SS-桥,被发现是一种有效的HDAC抑制剂。环肽7,环( -升-氨基酸d -氨基酸升-Val- d- Pro-)在第一个和第二个氨基酸之间带有-SS-桥,也是一种有效的HDAC抑制剂。
Live-Cell Protein Modification by Boronate-Assisted Hydroxamic Acid Catalysis
作者:Christopher Adamson、Hidetoshi Kajino、Shigehiro A. Kawashima、Kenzo Yamatsugu、Motomu Kanai
DOI:10.1021/jacs.1c07060
日期:2021.9.22
Selective methods for introducing protein post-translational modifications (PTMs) within living cells have proven valuable for interrogating their biological function. In contrast to enzymatic methods, abiotic catalysis should offer access to diverse and new-to-nature PTMs. Herein, we report the boronate-assisted hydroxamic acid (BAHA) catalyst system, which comprises a protein ligand, a hydroxamic
Isoquinolinylguanidine compounds of formula (I): ##STR1## wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.
A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.